Denosumab biosimilar by Sandoz Group for Post Menopausal Osteoporosis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Post Menopausal Osteoporosis.

Source link
#Denosumab #biosimilar #Sandoz #Group #Post #Menopausal #Osteoporosis #Likelihood #Approval